相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
Yuxin Huang et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study
Daisuke Suzuki et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Marc Evans et al.
DIABETES THERAPY (2020)
Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
Anne L. Peters et al.
DIABETES CARE (2020)
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors
Thomas Danne et al.
DIABETES CARE (2019)
Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and-2
Chantal Mathieu et al.
DIABETES CARE (2019)
Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes-The DEPICT-1 Study
Paresh Dandona et al.
DIABETES (2018)
Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes-DEPICT-2 Study
Chantal Mathieu et al.
DIABETES (2018)
SGLT inhibitor adjunct therapy in type 1 diabetes
Rory J. McCrimmon et al.
DIABETOLOGIA (2018)
ISPAD Clinical Practice Consensus Guidelines 2018: Assessment and management of hypoglycemia in children and adolescents with diabetes
Mary B. Abraham et al.
PEDIATRIC DIABETES (2018)
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state
Joseph I. Wolfsdorf et al.
PEDIATRIC DIABETES (2018)
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes in adolescence
Fergus J. Cameron et al.
PEDIATRIC DIABETES (2018)
ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes
Thomas Danne et al.
PEDIATRIC DIABETES (2018)
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock et al.
DIABETES CARE (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
Masaaki Miyauchi et al.
INTERNAL MEDICINE (2017)
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Satish K. Garg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
Toshiyuki Hayashi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Double-diabetes in a real-world sample of 2711 individuals: associated with insulin treatment or part of the heterogeneity of type 1 diabetes?
Fernando M. A. Giuffrida et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Arthur T. Sands et al.
DIABETES CARE (2015)
Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
Robert R. Henry et al.
DIABETES CARE (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
SGLT-2 inhibition and glucagon: Cause for alarm?
Richard G. Kibbey
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
Bruce A. Perkins et al.
DIABETES CARE (2014)
Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials
T Hach et al.
Diabetologie und Stoffwechsel (2014)
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael A. Nauck
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
Ralph A. DeFronzo et al.
DIABETES CARE (2013)
Effects of Dapagliflozin on Cardiovascular Risk Factors
Agata Ptaszynska et al.
POSTGRADUATE MEDICINE (2013)
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ele Ferrannini et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Obesity, Autoimmunity, and Double Diabetes in Youth
Paolo Pozzilli et al.
DIABETES CARE (2011)
Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth Study
Lenna L. Liu et al.
PEDIATRIC DIABETES (2010)
Metabolic origins and clinical significance of LDL heterogeneity
KK Berneis et al.
JOURNAL OF LIPID RESEARCH (2002)
分享论文
